SequelSEC

Lyell Immunopharma, Inc. LYEL

Pharmaceutical Preparations · CIK 0001806952 · Fiscal year ends 1231

Revenue
$27.00K
Fiscal year ended 2026-06-30
Operating income
-$256.50M
Fiscal year ended 2026-06-30
Free cash flow
-$133.97M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$129.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$5.53Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue3583.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Operating margin-748344.4%0th
SBC / revenue116191.7%100th
CapEx / revenue2166.7%100th
FCF margin-418900.0%0th
Net margin-762355.6%1th
Revenue YoY growth-41.0%26th
Current ratio5.28x62th

Lyell Immunopharma, Inc. (LYEL) reported revenue of $27.00K and net income of -$248.48M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Lyell Immunopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Lyell Immunopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$27.00K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$256.50M
Net income-$248.48M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$40.43M
Selling & marketingUnavailable

Balance

Lyell Immunopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$72.98M
Total assets$311.15M
Current assets$213.54M
Total liabilities$77.34M
Current liabilities$39.87M
Total equity incl. NCI$233.82M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$3.88M

Cash flow

Lyell Immunopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$133.26M
Capital expenditures$711.00K
Investing cash flow$4.98M
Financing cash flow$102.47M
Net change in cash-$25.82M
Stock-based compensation$39.63M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$9.52M

Derived

Lyell Immunopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$133.97M
Gross marginUnavailable
Operating margin-949981.5%
FCF margin-496188.9%
SBC / revenue146770.4%
Current ratio5.36x
Revenue YoY growth-55.0%
Net margin-920285.2%
R&D / revenueUnavailable
CapEx / revenue2633.3%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LYEL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.